Scientists at Oxford University are racing to develop
a vaccine for the coronavirus well ahead of the standard medical timeline.
The scientists have expressed confidence in their ability to do it quickly, raising hopes around the world that a vaccine will not have to wait until next year.
The first injections of the vaccine being developed by the university’s Jenner Institute in Britain took place last week. Scientists are planning to massively scale up their testing in a little over a month, a time frame that is currently faster than other vaccine development efforts.
The New York Times reported Monday that the scientists plan to test their vaccine on more than 6,000 people by the end of May.
The team at Oxford said their aim is to produce a million doses of the vaccine, if it proves effective, by September — months ahead of a standard timeline of 12 to18 months routinely quoted by health professionals around the world.
Professor Sarah Gilbert, team leader of the program, said she is “80% confident” the vaccine will work.
Britain’s Health Secretary Matt Hancock speaks during a daily news conference on the coronavirus outbreak, at 10 Downing Street in London, April 27, 2020.
Early trials promising
Because of that confidence, Britain has begun allocating funds for large-scale development, a move that is financially risky if the vaccine turns out to be ineffective.
“We are going to back them to the hilt and give them every resource they need to give them the best chance of success,” Britain’s Health Secretary Matt Hancock said last week.
The researchers’ confidence comes in part from the knowledge that the vaccine’s basic components have been genetically engineered to be harmless against humans and have been found to be safe in earlier trials.
Initial experiments also indicate the vaccine is effective, including tests that show it can generate a strong immune response in rhesus macaque monkeys.
The vaccine has been made from a common cold virus that has been modified so it cannot grow in people. Scientists have added proteins from the coronavirus that they hope will trigger the human immune system to produce antibodies against the protein, which will then protect against the actual virus.
Trials of the virus’s base components have been ongoing for years as part of an effort to find a malaria vaccine. Gilbert used the same modified virus to make a vaccine against an earlier coronavirus, MERS. Clinical trials of that vaccine are promising.
A traditional vaccine uses a weakened version of a virus to trigger an immune response in humans, and great care must be taken to ensure it is not only effective in humans but also safe.
A major reason the Oxford vaccine can quickly move through trials is that its base components have already undergone rigorous testing in humans.
FILE – In this March 19, 2020, photo, laboratory scientist Andrea Luquette cultures coronavirus to prepare for testing at U.S. Army Medical Research and Development Command at Fort Detrick in Frederick, Md.
Challenges
While early indications show the new vaccine is promising, one complication for the trials could paradoxically be the success of efforts to limit the spread of the disease in Britain.
For the vaccine data to be effective, subjects must be shown not to contract COVID-19 from their surroundings. However, if the disease is not spreading naturally around them, the trial might not be able to show whether the vaccine is making a difference, or it might take longer to reach conclusions.
Researchers say if they cannot get conclusive results in Britain, they might have to begin new trials in another part of the world where the virus is spreading more rapidly.
Ethics guidelines generally prohibit scientists from injecting healthy patients with a serious disease.
There are more than 100 efforts around the world to develop a vaccine for the coronavirus, but only a few have begun human trials.
U.S.-based Moderna was the first company to begin small clinical trials in March, but larger human trials have not begun.
Other efforts have come from the Chinese company CanSino, and a partnership between German biotech company BioNTech and U.S. pharmaceutical company Pfizer.
U.S. scientists say they were close to developing a coronavirus vaccine years ago to fight severe respiratory syndrome, or SARS, but that funding dried up when SARS disappeared after killing more than 770 people worldwide.
VOA
